martes, 22 de septiembre de 2015

17th International Congress on Infectious Diseases Hyderabad, India, March 2-5, 2016

17th International Congress on Infectious Diseases
Hyderabad, India, March 2-5, 2016

Dear Colleague,
 
We are excited to share the program for the 17th International Congress on Infectious Diseases to be held in Hyderabad, India on March 2-5, 2016http://www.isid.org/icid/
 
The program and plenary speakers encompass all fields in infectious diseases with particular attention being paid to the major infectious causes of morbidity and mortality in India and elsewhere. Diseases presented will include HIV, malaria, TB, vaccine preventable diseases, neglected diseases and many others. Current issues and the latest results related to these diseases will be presented in Hyderabad. I encourage you to visit the website for the meeting to find program updates, register for the meeting and also submit abstracts of your own work for presentation during the Congress.
 
Abstract submission instructions: http://www.isid.org/icid/abstract_guidelines.shtml and complete hotel and registration information http://www.isid.org/icid/registration_guide.shtml are also posted.
 
Please note the following important deadlines:
 
Abstract submission deadline:
            Abstract submission deadline: November 1, 2015
            Early registration fee deadline: January 10, 2016
 
We are looking forward to welcoming you to Hyderabad, the center of India.
 
Sincerely,
Britta Lassmann
ISID Program Director
17th ICID
ISID would like to acknowledge the 17th ICID Premier Sponsors:
Daiichi-Sankyo India Pharma Pvt. Ltd.
Pfizer
17th ICID Official Airline
17th ICID Official Airline
Travel on Etihad to Hyderabad, India

The ISID is pleased to announce that Etihad Airways has been selected as the official airline for the 17th ICID in Hyderabad, India. Etihad has excellent connections to Hyderabad from around the globe via Abu Dhabi with more than 100 destinations worldwide.

17th ICID Discount Codes are available, click here for more information.

No hay comentarios: